Smith & Nephew
- Market cap
- 11.25B
- P/E (TTM)i
- 18.29
- P/Bi
- 2.17
- EPSi
- 1.43
- Div yieldi
- 2.91%
- 52W posi
- 8%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Fair Value how this is computed
- Implied fair-value range of 32.16-67.62, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -46.1% below the average-multiple fair value of 49.89.
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Smith & Nephew (SNN) | 11.25B | 18.29 | 2.17 | 2.91% |
| Abbott Laboratories (ABT) | 170.84B | 31.95 | 3.34 | 2.47% |
| Medtronic (MDT) | 109.38B | 21.06 | 2.18 | 3.33% |
| Stryker Corp (SYK) | 105.64B | 28.54 | 4.40 | 1.26% |
| Boston Scientific (BSX) | 60.26B | 16.83 | 2.42 | 0.00% |
| Edwards Lifesciences (EW) | 49.44B | 49.87 | 4.66 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 32.1% below Morningstar's fair value estimate.
Fair value
Smith & Nephew PLC receives a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 24% discount to our quantitative fair value estimate of $35.52 per share, which is reinforced by this estimate's low uncertainty rating.
The company's valuation metrics bolster our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to EBITDA ratio of 6.5 lies in the bottom 20% compared with peers globally. Relative to the company's EBITDA, the enterprise value of the business is low, which contributes to our view that shares are cheap.
The company's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 8.0%, for example, falls in the top 30% compared with peers globally. This suggests that it is generating substantial earnings relative to its share price, which further promotes our favorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.
Economic moat
The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-10-08 07:36:10 · For reference only, not investment advice and not tailored to your situation.